Century Therapeutics Presented New Diabetes Therapy Data
The company showcased promising nonclinical results for its iPSC-derived islet replacement therapy in Milan.
Updated on Oct. 2, 2026 in Diabetes
Live Poll
Should medical regulators accelerate the approval process for experimental cell therapies to treat chronic diseases?
Century Therapeutics presented nonclinical data for its investigational diabetes therapy, CNTY-813, at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The FDA has reached general alignment with the company regarding the manufacturing process and design for a future Phase 1/2 clinical trial.
Why it matters
This therapy aims to treat type 1 diabetes by utilizing iPSC-derived islets to restore glycemic control. Alignment with federal regulators marks a significant milestone in advancing the product toward human clinical trials.
The therapy maintained glycemic control in mouse models for over 11 months and demonstrated cold storage functionality for 96 hours. Five clinical-scale manufacturing batches were produced using a 29-day process.
The players
Century Therapeutics
This Philadelphia-based biotechnology firm specializes in developing iPSC-derived cell therapies for various medical conditions.
FDA
The Food and Drug Administration is the federal agency responsible for regulating medical products and overseeing the approval of clinical trial designs.
European Association for the Study of Diabetes
This professional organization hosts annual meetings to share advancements in diabetes research and clinical practice.
The details
CNTY-813 uses Allo-Evasion 5.0 engineering technology to replace islet cells, which successfully retained their endocrine and beta cell identity in rat delivery tests. Century Therapeutics confirmed that clinical-scale batches produced consistent product profiles.
Timeline
October 2, 2026: Nonclinical data was presented at the EASD Annual Meeting.
Fourth quarter of 2026: The company expects to submit an Investigational New Drug application.
Second half of 2027: Initial clinical data from the CNTY-813 study is anticipated.
The Big Picture
This research follows the broader trajectory of iPSC-derived islet replacement therapies, which represent a significant shift toward cellular engineering to address type 1 diabetes. These results extend the current standard of islet cell research by demonstrating consistent scalability and cold-chain stability.
The development of long-lasting, off-the-shelf islet replacements could eventually provide patients with type 1 diabetes a more consistent way to manage blood sugar without daily insulin injections. While not yet available for human treatment, the progress indicates a potential future shift in how the disease is managed medically.
The takeaway
Advancements in cell manufacturing and engineering are bringing researchers closer to a reliable biological treatment for diabetes. These milestones suggest that scalable, ready-to-use cell therapies may soon become a viable pillar of chronic disease management.
What happens next
Century Therapeutics expects to submit an Investigational New Drug application in the fourth quarter of 2026, with the first clinical data anticipated in the second half of 2027.
Further reading
For more information on the latest advancements in cell-based treatments, visit our Diabetes section.
Live Poll
Should medical regulators accelerate the approval process for experimental cell therapies to treat chronic diseases?
